Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
about
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potentialSignatures of breast cancer metastasis at a glanceHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenInduction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor libraryGenomancy: predicting tumour response to cancer therapy based on the oracle of genetics.ArrayMining: a modular web-application for microarray analysis combining ensemble and consensus methods with cross-study normalization.Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics.Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signaturesSystematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples.Genome-based risk prediction for early stage breast cancer.A prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model.The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.The 70-gene prognostic signature for korean breast cancer patients.Application of a 70-Gene Expression Profile to Japanese Breast Cancer PatientsThe 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer.Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patientsAn "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.Positive expression of miR-361-5p indicates better prognosis for breast cancer patients.Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience.Molecular profiling for breast cancer: a comprehensive review.Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.The future of diagnostic gene-expression microarrays: bridging the gap between bench and bedside.Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.The challenges of individualized care for older patients with localized breast cancer.Multi-gene classifiers for prediction of recurrence in breast cancer patients.Gene-Expression-Based Predictors for Breast Cancer.Understanding the cancer cell phenotype beyond the limitations of current omics analyses.A long-range interactive DNA methylation marker panel for the promoters of HOXA9 and HOXA10 predicts survival in breast cancer patients.Clinical utility of gene-expression signatures in early stage breast cancer.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Use of a genomic test (MammaPrint™) in daily clinical practice to assist in risk stratification of young breast cancer patients.Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.
P2860
Q26782613-50F6B6C0-D747-4A43-AD17-2971F11EE188Q28071451-204C6F94-71B5-4D66-BF33-12A757394CC9Q28077637-10FD0E5F-4720-4E12-8DAB-5E1287DF6CF1Q28479198-FE74A3C8-4EC4-457A-85D4-02580C7D8D93Q30440216-25B78A97-8BDC-4208-94E6-DBAFEAF33AC1Q30491604-22F409D8-3D57-40FF-B679-4923591DD2D3Q33736432-BE380434-4F31-42EF-B97E-48F0420ECFA5Q33834198-EAF4620D-F68D-4536-B66D-E1D1CC0A326CQ33886387-AB7CDAC7-6916-4EF6-B2CF-C2510934655CQ33947222-671CC12C-5795-4B0A-B22F-F16E485EBEDEQ34359289-8B85E38D-86A1-4BAF-B64F-D6733C705EBEQ34658145-BE9CF507-625F-4C06-A98E-5C10B1A7A129Q35007777-C7012BDC-BB53-463C-9E4D-3643D521370CQ35142098-67DE5669-37D6-4F3A-93B2-5D54091486B1Q35726008-70347BD1-79E4-4F5E-8D8B-660F645D4AD6Q35909546-4E8B77F0-8C4B-49B3-8808-1A4F9D312422Q35913234-53D4C1F4-C93A-485E-9728-0CA05AB756A4Q36117673-F6E70F43-EFB9-4B5C-9598-6FFC923870A8Q36187733-2D94C884-38DD-4F66-805D-D1D7887E869AQ37121435-F304C689-E508-401E-A003-41B270A6C2CCQ37214212-2373E148-C19E-4B2B-BFED-3713D34074FDQ37214217-0050060E-46BE-4175-9405-D736EBBBE8B2Q37288135-D0A510A1-E0BD-495C-9994-14CD665938AAQ37302484-F17C26B8-E61A-4E99-87BA-AECCAAB07A51Q37321086-5483D7C0-865D-404B-8140-38742B9E3635Q37383276-2959A84D-BA7E-4CDB-9315-F57DC0BAF3E0Q37542251-A698001B-8ED1-4DA4-B265-438B18C4061CQ37810248-A8171995-D513-4F06-A513-4DCC956E2ED5Q37884483-A84553E5-63B4-4853-85CD-D5640DC56204Q38024305-53EA5D24-AFCD-498B-A16A-6F0465BBC0A6Q38107101-BA2BF31A-107F-4B21-AF8E-1A8FD0E5A670Q38132244-698F4B29-A980-4860-85CC-07A961FB18DCQ38362985-E13C1624-D63B-43C1-9C43-46109F90966EQ38555220-759F0B00-DB3F-45CE-92E3-C7572C029A60Q38595074-AAB76CA7-6C0A-4733-B287-3D075CA7C667Q38658847-B3B1860D-7A8F-449F-B9A3-9772760E363BQ38754717-044304FE-B020-47A4-8716-B71273000AF3Q39187437-0E77A874-7F4D-4114-A3CA-FD9162552CDEQ39883861-6652CD7D-BD28-4CAC-81BD-2331AB0FD2FCQ41113513-18A51008-A9A7-4FBA-B3A5-85E473A6455D
P2860
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@ast
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@en
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@nl
type
label
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@ast
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@en
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@nl
prefLabel
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@ast
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@en
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@nl
P2093
P2860
P1476
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
@en
P2093
Anitha Male
Annuska M Glas
Ben S Wittner
Daniel A Haber
Dennis C Sgroi
Laura J Van't Veer
Paula D Ryan
Sonika Dahiya
Sridhar Ramaswamy
Tako J Bruinsma
P2860
P304
P356
10.1158/1078-0432.CCR-07-4723
P407
P577
2008-05-01T00:00:00Z